Eli Lilly ((LLY) reported strong quarterly results on Thursaday morning, with revenue increasing 36%, driven primarily by the success of Mounjaro, Zepbound, and Verzenio. The company also saw a significant increase in earnings per share (EPS), up 68% year-on-year and eclipsing analysts’ estimates by 42%.Eli Lilly raised its full-year revenue guidance by $3 billion and increased its EPS guidance. Additionally, the company highlighted major progress in its pipeline, including the approval of Kisunla for Alzhe ...